Molecular Pathology and Targeted Therapy Quiz

In recurrent ovarian cancer, which factor best identifies patients who could benefit from PARP inhibitors?
HRD status
Response to platinum-based therapy
Previous Platinum-free interval
For First line therapy of High grade serous ovarian cancer with PARP inhibitors, what percentage of patients have HRD in the tumour?
15%
25%
50%
Which is the molecular type of endometrial carcinoma, most likely associated with good prognosis?
p53 abnormal
Non specific molecular profile
Mismatch Repair Deficient
Pole mutated
{"name":"Molecular Pathology and Targeted Therapy Quiz", "url":"https://www.quiz-maker.com/QGIHKFE7B","txt":"In recurrent ovarian cancer, which factor best identifies patients who could benefit from PARP inhibitors?, For First line therapy of High grade serous ovarian cancer with PARP inhibitors, what percentage of patients have HRD in the tumour?, Please enter your email address","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
Powered by
Quiz Maker
Powered by: Quiz Maker